drugset / Trial / NCT03318744

Antiplatelet Therapy for Silent Brain Infarction

NCT03318744

Unknown 3400 enrolled First People's Hospital of Shenyang
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Silent brain infarction (SBI) or incidental infarct is common. Recent studies revealed individuals with SBI have an increased risk of future stroke. Even though the 2014 AHA/ASA recommendation for ischemic stroke and transient ischemic attack considered SBI as an entry point for secondary prevention, convincing evidence with regard to the preventive efficacy of antiplatelet therapy against incident stroke in SBI is scant. Investigators examine if antiplatelet therapy can effectively decrease the incidence of future stroke in SBI individuals.

Timeline

Start
2018-01
Primary completion
2021-07
Completion
2021-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Aspirin Small molecule 100 mg Oral

Indications